These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7354931)

  • 1. [Epidemiological evaluation of thromboembolic risk. Critical review of the prospects offered by determination of antithrombin III].
    Gabrielli L; Lorenzi G; Sarcina A; Rossi E; Margstakler E; Mondonico P
    Minerva Med; 1980 Jan; 71(2):83-8. PubMed ID: 7354931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The physiological inhibitors of blood coagulation. 1. Antithrombin III (AT III)].
    Kase F; Pospísil J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(3):337-49. PubMed ID: 6194066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Activity of antithrombin III in the blood of patients with bladder cancer].
    Zietek Z; Iwan-Zietek I; Kotschy M; Wiśniewska E; Tyloch F
    Pol Merkur Lekarski; 1997 Apr; 2(10):268-9. PubMed ID: 9377663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III deficiency, deep venous thrombosis, and oral contraceptive use.
    Werner MJ
    J Adolesc Health; 1995 Sep; 17(3):189-92. PubMed ID: 8519788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assay of antithrombin III and soluble fibrin complexes in the study of blood thrombophilia (author's transl)].
    Colombo LA; Corberi OM; Finzi M; Rossi G
    Chir Ital; 1979 Aug; 31(4):650-61. PubMed ID: 553732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of antithrombin III in kidney diseases].
    Schrader J; Köstering H; Scheler F
    Behring Inst Mitt; 1986 Feb; (79):216-30. PubMed ID: 3718408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple thromboembolism associated with anti-thrombin III deficiency].
    Catarino C; Silva PM; Quininha J; Serra J; da Silva N; Antunes E; Ferreira R; de Oliveira M; Gracias R; Prates A
    Acta Med Port; 1991; 4(3):157-9. PubMed ID: 1950667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias.
    Pini M; Scoditti U; Caliumi F; Manotti C; Quintavalla R; Pattacini C; Poli T; Tagliaferri A; di Iasio MG; Bernardi F
    Recenti Prog Med; 1996; 87(7-8):331-7. PubMed ID: 8831253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antithrombin III, the most important inhibitor of hemostasis. Physiology and clinical aspects].
    Neubauer M; Ramschak H; Lanzer G
    Wien Med Wochenschr; 1986 Nov; 136(21-22):560-2. PubMed ID: 3825161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombin III and its role in normal and pathological hemostasis].
    Bŭchvarova V; Doĭchinov A; Angelova N
    Vutr Boles; 1981; 20(6):34-8. PubMed ID: 7039127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of thrombophilia and venous thromboembolism in total knee arthroplasty.
    Chotanaphuti T; Ongnamthip P; Silpipat S; Foojareonyos T; Roschan S; Reumthantong A
    J Med Assoc Thai; 2007 Jul; 90(7):1342-7. PubMed ID: 17710975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease.
    Mader R; Ziv M; Adawi M; Mader R; Lavi I
    J Rheumatol; 1999 Nov; 26(11):2404-8. PubMed ID: 10555901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of antithrombin III in thrombogenesis: the diagnosis and therapy of antithrombin III defects].
    Wenzel E; Hellstern P; Dumitrescu-Demma E; Miyashita C; Köhler M
    Z Gesamte Inn Med; 1984 May; 39(10):220-7. PubMed ID: 6464516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of hemostasis in venous thromboembolism pathology].
    Gaussem P; Siguret V; Aiach M
    Ann Biol Clin (Paris); 1998; 56(1):49-56. PubMed ID: 9754222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin.
    Hoffmann JN; Wiedermann CJ; Juers M; Ostermann H; Kienast J; Briegel J; Strauss R; Warren BL; Opal SM;
    Thromb Haemost; 2006 May; 95(5):850-6. PubMed ID: 16676077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery.
    F Shepherd M; Rosborough TK; Schwartz ML
    Obes Surg; 2004 May; 14(5):601-5. PubMed ID: 15186625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease.
    Novacek G; Miehsler W; Kapiotis S; Katzenschlager R; Speiser W; Vogelsang H
    Am J Gastroenterol; 1999 Mar; 94(3):685-90. PubMed ID: 10086652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulopathic complications in breast cancer.
    Caine GJ; Stonelake PS; Rea D; Lip GY
    Cancer; 2003 Oct; 98(8):1578-86. PubMed ID: 14534872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis of hypercoagulability].
    Vinazzer H
    Wien Klin Wochenschr; 1984 Dec; 96(24):872-5. PubMed ID: 6528615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.